SEC Form 4 · accession 0000899243-18-020454

CONSTELLATION PHARMACEUTICALS INC · CNST

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

Period of report

Jul 23, 2018

Accepted (ET)

Jul 23, 2018 · 8:08 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001434418

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jul 23, 2018	C	349,853	—	A	349,853	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series E Preferred Stock^F2,F1	—	Jul 23, 2018	C	888,888	D	—	—	Common Stock	103,811	D
Series E-1 Preferred Stock^F2,F1	—	Jul 23, 2018	C	1,208,678	D	—	—	Common Stock	109,788	D
Series F Preferred Stock^F2,F1	—	Jul 23, 2018	C	1,500,000	D	—	—	Common Stock	136,254	D

F1On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
F2The securities are directly held by Spur Ventures II, L.P., and indirectly held by Spur Capital Partners, LLC, the manager of Spur Ventures II, L.P. Spur Capital Management II, LLC is the general partner of Spur Ventures II, L.P. Spur Capital Partners, LLC may be deemed to have voting and investment power with respect to such shares.